Intellia Posts Q2 Loss, Extends Cash Runway to 2028; CEO Adopts 10b5-1 Plan
NTLA sits 45% above its 52-week low of $7.95.
Summary
Intellia Therapeutics posted a Q2 2026 net loss of $106.6 million and extended its cash runway into 2028. The CEO modified a 10b5-1 trading plan, and the company disclosed a lease termination along with updated risk factors.
Key Events · Earnings and Guidance · NTLA
-
Q2 2026 Financial Results
A net loss of $106.6 million was recorded on collaboration revenue of $7.7 million. R&D expenses fell 15% year-over-year to $82.6 million, while G&A rose 39% to $37.8 million as the commercial buildout continues.
-
Cash Runway Extended into 2028
Cash, cash equivalents, and marketable securities stood at $628.4 million as of June 30, 2026, a balance expected to fund operations into 2028, excluding any potential milestone payments or commercial revenues.
-
CEO Modifies 10b5-1 Trading Plan
On May 21, 2026, CEO John M. Leonard modified a Rule 10b5-1 trading arrangement that allows for the potential sale of up to 245,192 shares through December 18, 2028.
-
Lease Termination Streamlines Real Estate
The lease for 130 Brookline Street was amended, shortening the term to December 31, 2026, in exchange for a $3.9 million fee, which reduced right-of-use assets by $2.1 million.
Analysis · NTLA · Life Sciences
Intellia's second quarter delivered a net loss of $106.6 million on collaboration revenue of $7.7 million, while R&D spending declined as the company sharpens its focus on lead programs. Cash and marketable securities total $628.4 million, providing a runway into 2028. Separately, CEO John Leonard modified a pre-arranged stock sale plan covering up to 245,192 shares, and the company terminated a lease early to streamline its real estate footprint. These updates arrive alongside positive Phase 3 data for lonvo-z and the resumption of nex-z trials after a clinical hold was lifted.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $11.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.95 to $28.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.